IPO registrations (S-1, F-1) · Registrants

Century Therapeutics, Inc.

SEC CIK
1850119 · filings on EDGAR ↗
Registration
Form S-1, first filed 2021-05-28, last 2021-06-15; 1 initial registration, 2 amendments
Outcome
Final prospectus filed 2021-06-21; declared effective 2021-06-17
Industry (SIC)
Biological Products, (No Diagnostic Substances) 2836
Incorporated in
DE
Business address
25 N 38TH STREET, 12TH FLOOR, Philadelphia, PA
EIN
84-2040295
Ticker
IPSC (Nasdaq)
EDGAR entity type
operating
Insiders and CEO pay
Century Therapeutics, Inc. on the corporate pages

Offering terms

Proposed price range
$18.00–$20.00 per share (S-1/A filed 2021-06-15)
Final price
$20.00 per share, within the range (424B4 filed 2021-06-21, an initial public offering)
Shares sold
10,550,000
Gross proceeds
$211,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol IPSC
Lead underwriters
J.P. Morgan; BofA Securities; Leerink Partners; Piper Sandler

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 6

FiledFormWhat it isName as filedEDGAR
2021-05-28S-1S-1 (registration)Century Therapeutics, Inc.0001104659-21-074278 ↗
2021-06-14S-1/AS-1/A (amendment)Century Therapeutics, Inc.0001104659-21-080429 ↗
2021-06-15S-1/AS-1/A (amendment)Century Therapeutics, Inc.0001104659-21-081561 ↗
2021-06-17EFFECTEFFECT (declared effective)Century Therapeutics, Inc.9999999995-21-002398 ↗
2021-06-21424B4424B4 (final prospectus)Century Therapeutics, Inc.0001104659-21-082886 ↗
2022-07-13EFFECTEFFECT (declared effective)Century Therapeutics, Inc.9999999995-22-002060 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2021-06-15S-1/Aregistration statement$18.00–$20.0010,550,000-Nasdaq IPSC4primary document; range, shares headline, cover names 4document ↗
2021-06-21424B4final prospectus$20.0010,550,000$211,000,000Nasdaq IPSC4primary document; price sentence, shares headline, proceeds table, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
BAYER AKTIENGESELLSCHAFTTenPercentOwner22021
Bayer World Investments B.V.TenPercentOwner22021
Blackwell KimberlyDirector72021–2026
Borges LuisOfficerChief Scientific Officer52021–2023
BUTITTA CYNTHIA MDirector62021–2025
Carlo RizzutoDirector62021–2025
Carr DouglasOfficerSVP Finance & Operations; VP Finance & Operations; VP of Finance and Operations292021–2026
Casdin EliDirector42021–2022
Diem Michael CraigOfficerChief Business Officer; Chief Financial Officer52021–2023
Farid AdrienneOfficerChief Operations Officer142021–2025
Flores OsvaldoDirector,Officer; OfficerChief Executive Officer32021–2023
FUJIFILM Cellular Dynamics, Inc.TenPercentOwner22021
FUJIFILM CorpTenPercentOwner22021
FUJIFILM Holdings America CorpTenPercentOwner22021
FUJIFILM Holdings CorpTenPercentOwner22021
JIMENEZ JOSEPHDirector62021–2025
Levitsky HyamOfficerPresident of R&D52021–2024
Riva AlessandroDirector72021–2026
Russotti GregoryOfficerChief Technology Officer; See Remarks232021–2026
Versant Vantage II GP-GP, LLCTenPercentOwner52021–2022
Versant Vantage II GP, L.P.TenPercentOwner52021–2022
Versant Vantage II, L.P.TenPercentOwner52021–2022
Versant Venture Capital VI, L.P.TenPercentOwner52021–2022
Versant Ventures VI GP-GP, LLCTenPercentOwner52021–2022
Versant Ventures VI GP, L.P.TenPercentOwner52021–2022
Quimi DaphneDirector72022–2026
Walbert Timothy PDirector52022–2025person page Fuzzy
Pfeiffenberger BrentDirector,OfficerPresident and CEO242023–2026
Cowan ChadOfficerChief Scientific Officer112024–2026
Conn MorganOfficerChief Financial Officer; Chief Finanical Officer32024–2025
Lee Han MyungDirector32025–2026
Murphy Martin PatrickDirector32026
Truitt JosephDirector22026

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2021-03-15Century Therapeutics, Inc.Other Health Care$160,000,000$0221

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationCentury Therapeutics, Inc.PAState business registriesname and state
Plan sponsorCENTURY THERAPEUTICS, INC.PAForm 5500 (employee benefit plans)EIN (EXACT)
Form D issuerCentury Therapeutics, Inc.PAForm D private offeringsCIK (EXACT)
Patent assigneeCentury Therapeutics, Inc.PAPatents (USPTO)name and state
SEC filerCentury Therapeutics, Inc.SEC filers (EDGAR)CIK (EXACT)
Trademark ownerCentury Therapeutics, Inc.PATrademarks (USPTO)name and state
Form 5500 plan sponsorCENTURY THERAPEUTICS, INC.EIN (EXACT)
Person pageTimothy P WalbertPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Biological Products, (No Diagnostic Substances), PA first:

More with this interest.

In other datasets, the same topic (Health) in PA:

Interests: Biological Products, (No Diagnostic Substances) · Health